MRI pharmaceutical developer Epix Medical of Cambridge, MA, has submitted a new drug application (NDA) to the Food and Drug Administration for its MS-325 vascular contrast agent.
The agent is specifically designed for magnetic resonance angiography (MRA) and was co-developed by Epix and Schering of Berlin. The MS-325 NDA is the first application for marketing approval for an MR contrast agent to be submitted to the FDA for the primary indication of MRA, Epix said.
By AuntMinnie.com staff writersDecember 16, 2003
Related Reading
Epix COO resigns, November 11, 2003
Epix continues to build revenues, trim losses in Q3, October 24, 2003
Epix to present phase III results, September 15, 2003
Epix exercises overallotment option, August 27, 2003
Epix sets share price, August 7, 2003
Copyright © 2003 AuntMinnie.com
